Development of an improved Epstein-Barr virus (EBV) neutralizing antibody assay to facilitate development of a prophylactic gp350-subunit EBV vaccine

Hui Liu, Lorraine Gemmell, Rui Lin, Fengrong Zuo, Henry H. Balfour, Jennifer C. Woo, Gregory M. Hayes

Research output: Contribution to journalArticlepeer-review

Abstract

No licensed vaccine is available for prevention of EBV-associated diseases, and robust, high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed an improved EBV-GFP based neutralization assay for such a vaccine's pre-clinical and clinical validation to measure EBV specific neutralizing antibodies in human donors. The supplementation of guinea pig complement of our previously published high-throughput EBV-GFP fluorescent focus (FFA)based neutralization assay allowed the detection of complement-dependent neutralizing antibodies using a panel of heat-inactivated healthy human sera. Anti-gp350 antibody titers, which were evaluated using a previously optimized anti-gp350 IgG ELISA assay, were moderately correlated to the FFA-based neutralization titers. Overall, this improved high-throughput neutralization assay is capable of characterizing the serologic neutralizing antibody response to natural EBV infection, with applications in evaluating EBV antibody status in epidemiologic studies and immunogenicity of candidate gp350-subunit EBV vaccines in clinical studies.

Original languageEnglish (US)
Article numbere2020016
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume12
Issue number1
DOIs
StatePublished - 2020

Bibliographical note

Funding Information:
We thank Dr. Lindsey Hutt-Fletcher (Louisiana State University) for providing Akata-BX1-g cell line and SVK-CR2 cell line. We also thank Hong Jin (MedImmune/AstraZeneca) for editing the manuscript.

Keywords

  • Anti-gp350 IgG ELISA
  • Epstein-Barr Virus
  • Gp350
  • Neutralization assay
  • Vaccine

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Development of an improved Epstein-Barr virus (EBV) neutralizing antibody assay to facilitate development of a prophylactic gp350-subunit EBV vaccine'. Together they form a unique fingerprint.

Cite this